Inhibitor Therapeutics Stock Performance
| INTI Stock | USD 0.04 0 7.79% |
On a scale of 0 to 100, Inhibitor Therapeutics holds a performance score of 2. The company retains a Market Volatility (i.e., Beta) of -1.01, which attests to a somewhat significant risk relative to the market. As the market becomes more bullish, returns on owning Inhibitor Therapeutics are expected to decrease slowly. On the other hand, during market turmoil, Inhibitor Therapeutics is expected to outperform it slightly. Please check Inhibitor Therapeutics' total risk alpha and the relationship between the potential upside and price action indicator , to make a quick decision on whether Inhibitor Therapeutics' current trending patterns will revert.
Risk-Adjusted Performance
Weak
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Inhibitor Therapeutics are ranked lower than 2 (%) of all global equities and portfolios over the last 90 days. Despite fairly weak basic indicators, Inhibitor Therapeutics demonstrated solid returns over the last few months and may actually be approaching a breakup point. ...more
Inhibitor |
Inhibitor Therapeutics Relative Risk vs. Return Landscape
If you would invest 4.90 in Inhibitor Therapeutics on September 28, 2025 and sell it today you would lose (0.40) from holding Inhibitor Therapeutics or give up 8.16% of portfolio value over 90 days. Inhibitor Therapeutics is currently generating 0.2614% in daily expected returns and assumes 9.4163% risk (volatility on return distribution) over the 90 days horizon. In different words, 84% of otc stocks are less volatile than Inhibitor, and 95% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Inhibitor Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Inhibitor Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of otc stocks, such as Inhibitor Therapeutics, and traders can use it to determine the average amount a Inhibitor Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0278
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | INTI | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Based on monthly moving average Inhibitor Therapeutics is performing at about 2% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Inhibitor Therapeutics by adding it to a well-diversified portfolio.
Inhibitor Therapeutics Fundamentals Growth
Inhibitor OTC Stock prices reflect investors' perceptions of the future prospects and financial health of Inhibitor Therapeutics, and Inhibitor Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Inhibitor OTC Stock performance.
| Return On Asset | -2.11 | |||
| Current Valuation | 26.98 M | |||
| Shares Outstanding | 376.86 M | |||
| Price To Earning | (4.67) X | |||
| Price To Book | 76.91 X | |||
| EBITDA | (283.8 K) | |||
| Cash And Equivalents | 24.95 K | |||
| Total Debt | 331 K | |||
| Debt To Equity | 11.81 % | |||
| Book Value Per Share | (0.02) X | |||
| Cash Flow From Operations | (220.43 K) | |||
| Earnings Per Share | (0) X | |||
| Total Asset | 58.78 K | |||
| Retained Earnings | (60.33 M) | |||
| Current Asset | 2.39 M | |||
| Current Liabilities | 736.4 K | |||
About Inhibitor Therapeutics Performance
By evaluating Inhibitor Therapeutics' fundamental ratios, stakeholders can gain valuable insights into Inhibitor Therapeutics' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Inhibitor Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Inhibitor Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
Inhibitor Therapeutics, Inc., a pharmaceutical development company, develops and commercializes therapeutics for patients with certain cancers and non-cancerous proliferation disorders in the United States. Inhibitor Therapeutics, Inc. was founded in 1992 and is based in Tampa, Florida. Inhibitor Therapeutics operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 1 people.Things to note about Inhibitor Therapeutics performance evaluation
Checking the ongoing alerts about Inhibitor Therapeutics for important developments is a great way to find new opportunities for your next move. OTC Stock alerts and notifications screener for Inhibitor Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Inhibitor Therapeutics had very high historical volatility over the last 90 days | |
| Inhibitor Therapeutics has some characteristics of a very speculative penny stock | |
| Inhibitor Therapeutics currently holds 331 K in liabilities with Debt to Equity (D/E) ratio of 11.81, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Inhibitor Therapeutics has a current ratio of 0.04, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Inhibitor Therapeutics until it has trouble settling it off, either with new capital or with free cash flow. So, Inhibitor Therapeutics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Inhibitor Therapeutics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Inhibitor to invest in growth at high rates of return. When we think about Inhibitor Therapeutics' use of debt, we should always consider it together with cash and equity. | |
| Net Loss for the year was (298.63 K) with profit before overhead, payroll, taxes, and interest of 0. | |
| Inhibitor Therapeutics currently holds about 24.95 K in cash with (220.43 K) of positive cash flow from operations. | |
| Roughly 79.0% of Inhibitor Therapeutics shares are held by company insiders |
- Analyzing Inhibitor Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Inhibitor Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Inhibitor Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Inhibitor Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Inhibitor Therapeutics' management team can help you assess the OTC Stock's leadership.
- Pay attention to analyst opinions and ratings of Inhibitor Therapeutics' otc stock. These opinions can provide insight into Inhibitor Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Inhibitor OTC Stock analysis
When running Inhibitor Therapeutics' price analysis, check to measure Inhibitor Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Inhibitor Therapeutics is operating at the current time. Most of Inhibitor Therapeutics' value examination focuses on studying past and present price action to predict the probability of Inhibitor Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Inhibitor Therapeutics' price. Additionally, you may evaluate how the addition of Inhibitor Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences |